



FUNGUS CAN HIDE FROM

Sporanox^{*}

itraconazole 100 mg

One of the notorious problems with fungal infections of the skin or the vagina is that the organism may penetrate the deeper layers of the epithelium, out of reach of topical medication. And besides, when treating fungal skin lesions locally, the infection is often already subclinically present at other sites of the body, waiting for a chance to start the trouble all over again.

Because Sporanox works orally, i.e. "from the inside out", it will destroy even the best hidden fungal cells. All the more so, because Sporanox has a strong affinity for epidermal and mucosal tissues as well as for the fungal cell wall itself where it must exert its fungicidal activity.

SHORT AND SIMPLE ORAL THERAPY

Standard dose in Dermatology: 1 capsule (100 mg) once daily for 15 days
(Sporanox will remain active in the stratum corneum for another 3-4 weeks)

Standard dose in Gynaecology: 2 x 2 capsules (400 mg) for 1 day only
(Sporanox will remain active in the vaginal epithelium for another 3 to 4 days)

This product is not yet available in all countries.

*** Trademarks: SPORANOX, SEMPERA, TRISPORAL, SPORAL.**

Properties: Sporanox (itraconazole), a triazole derivative, is orally active against infections with dermatophytes (*Trichophyton* spp., *Microsporum* spp., *Epidermophyton floccosum*), yeasts (*Candida* spp., *Pityrosporum* spp.), *Aspergillus* spp. and various other yeasts and fungi. **Indications:** Sporanox (itraconazole) is indicated for vulvovaginal candidiasis, pityriasis versicolor, dermatophytosis, tinea corporis and tinea cruris. **Dosage and administration:** For tinea corporis and tinea cruris: 2 cap-

sules (200 mg) morning and evening for 1 day, Pityriasis versicolor: 2 capsules (200 mg) once daily for 7 days. - Tinea corporis, tinea cruris, tinea pedis, tinea manus: 1 capsule (100 mg) daily for 15 days; highly keratinized regions, as in plantar tinea pedis and palmar tinea manus, require 1 capsule (100 mg) daily for 30 days. - Oral candidosis: 1 capsule (100 mg) daily for 15 days. - Fungal keratitis: 2 capsules (200 mg) once daily for 21 days. **Contra-indications:** Sporanox (itraconazole) is contra-indicated during pregnancy. **Warnings and precautions:** Although clinically Sporanox (itraconazole) has not been associated with hepatic dysfunction, it is

advisable not to give this drug to patients with a known history of liver disease. **Nursing mothers:** It is recommended not to breast feed whilst taking Sporanox (itraconazole). **Drug interactions:** Sporanox (itraconazole) should not be given concomitantly with rifampicin.

Full prescribing information is available on request.

 **JANSSEN**
PHARMACEUTICA
2340 Beerse, Belgium
the drug discovery company

A N I N T E R N A T I O N A L J O U R N A L

Editor: Ronald M Davis

TOBACCO CONTROL is a new quarterly scientific journal launched in March 1992 by the BMJ Publishing Group to consider all aspects of tobacco prevention and control.

The Journal aims to study:

- The nature and extent of tobacco use worldwide
- The effect of tobacco use on health, the economy, the environment and society.
- The efforts of the health community and health advocates to prevent and control tobacco use
- The activities of the tobacco industry and its allies to promote tobacco use

The editorial team includes regional editors from throughout the world, associate editors with expertise in special areas, and an editorial advisory board of leading tobacco researchers and tobacco control advocates.

Research Areas:

- Evaluation of smoking prevention and cessation programmes
- Tracking and evaluation of tobacco control policies and legislation.
- Epidemiologic and behavioural research on tobacco use
- Health effects of smoking, smoking cessation, passive smoking and smokeless tobacco use.

Papers from Volume One:

- Trends in physicians' giving advice to stop smoking, United States, 1974-87
E Gilpin, J Pierce, J Goodman, G Giovino, C Berry, D Burns
- Targeting of cigarette advertising in US magazines, 1959-86
K E Warner, L M Goldenhar
- Recent developments in tobacco litigation, 1991
R A Daynard
- Support for restricting smoking at workplaces in developing countries: a survey of Peace Corps staff
T R Eng, S L Emont, T H van der Vlugt

Papers for submission should be sent to:

Ronald M Davis, MD
Editor: Tobacco Control
Michigan Department of Public Health
3423 North Logan Street
PO Box 30195
Lansing, Michigan 48909
USA

Subscription Rate

Worldwide £80, *Personal £50
(USA only \$ 140, *Personal \$87)

*Personal rates are only available on orders placed directly with the Publisher and paid for out of personal funds.

TURBIDITY CONTROL

ISSN 0004-4563

PUBLICATION: QUARTERLY

1992 subscription rate:

Worldwide £80, *Personal £50

(USA only \$140, *Personal \$87)
*Personal rate are only available on orders placed directly with the Publisher and paid for out of personal funds.

Please note

- ☐ Please send my subscription, start date _____
- ☐ Please send me a sample copy _____
- ☐ Please send me instructions to Authors _____
- ☐ Enclose a cheque for _____
(to purchase the *British Medical Journal*)
- ☐ I wish to pay by credit card.
American Express/Visa (Barclaycard)/Mastercard
(Date of signature) _____

Conclusion

[illegible]

Signature Card users should add the numbers appearing above their names.

Expiry Date:

Signature

(and agreement is voluntary, especially when dealing privately and)

Name (Cont'd)

Address

1997

Send orders to: Journals Marketing Dept., BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR
or BMJ Publishing Group, Box 1500, Boston, MA 02115, USA (Direct Orders Only)

BMI

Essential handbook of vascular diseases

Vascular problems are common – so much so that they are often forgotten and sometimes overlooked – and the incidence of vascular disease has increased to epidemic proportions. But along with this increase has come the rapid development of new methods of diagnosis and treatment. Successful management now requires cooperation among many hospital specialists – vascular surgeons, general surgeons, radiologists, neurologists, cardiologists, orthopaedic surgeons, and general physicians – as well as paramedical staff. A key figure in the equation is the general practitioner, who has a vital part to play throughout. The *ABC of Vascular Diseases* draws together the contributions of all these, condensing years of experience into brief chapters with clear practical messages. Aspects covered include the assessment of severity of disease and medical and radiological treatment as well as surgery. Both early and late complications are covered in detail, making this an essential handbook for everyone concerned in the treatment and rehabilitation of patients with vascular disease.

Published June 1992

UK £12.95; Abroad £15.00
BMA members £11.95 or £14.00
including postage, by air abroad

Available from: **BRITISH MEDICAL JOURNAL**,
PO Box 295, London WC1H 9TE, medical booksellers
or the **BMJ** bookshop in BMA House

Please send me _____ copy/ies of
ABC OF VASCULAR DISEASES

I enclose _____ Please make cheques payable
to **British Medical Journal**

Debit my credit card (please tick box)

☐ Visa ☐ American Express ☐ Mastercard

Card No. _____

Card expiry date _____

Signature _____


BMA Membership No. _____


NAME _____

ADDRESS _____

_____ POSTCODE _____

☐ Please send me a **BMJ** book catalogue
Book tokens accepted (UK only)





In his introduction to *More Everyday Aids and Appliances* Professor Graham Mulley, of the Department of Medicine for the Elderly, St James's University Hospital, Leeds, sums up the book's aims and approach. A companion volume to the popular *Everyday Aids and Appliances*, this new publication describes three kinds of aids – those that enable people to manage at home despite impaired mobility, those that improve mobility both at home and outside, and appliances that compensate for loss of or damage to, for example, eyes, teeth, or hair. Chapters include:

- Bed aids for home nursing
- Emergency alarms
- Kitchen aids
- Aids for disabled drivers
- Mobility aids and appliances for disabled children
- Breast prostheses

UK £8.95; Abroad £11.00
(BMA members £8.45 or £10.50)

Practical advice for the disabled

"The practical and uncomplicated approach . . . is refreshing . . . a useful guide for general practitioners and other health care personnel unfamiliar with the broad range of aids and appliances available to the disabled person."

Clinical Rehabilitation


"... contains a wealth of information about a wide range of currently available aids and appliances."

Journal of the Royal College of General Practitioners

"... very practical and down to earth little book. . . . particularly suitable for the medical practitioner, especially GPs."

Clinical Physics & Physiological Measurement

UK £6.95; Abroad £8.00 (BMA members £6.45 or £7.50)



ORDER FORM **British Medical Journal, PO Box 295, London WC1H 9TE.**

Please send me the following books:

QTY	TITLE	AUTHOR/EDITOR	AMOUNT
Prices include postage, by air abroad			TOTAL £

NAME _____
(print clearly)

ADDRESS _____

POSTCODE _____

☐ Please send me a book catalogue

Membership No _____

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____ Exp _____

Signature _____

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House.

BMA members £10.95 or £12.50

BMA members £8.45 or £9.50



BMA members £10.95 or £12.50

☐ Please send me a BMJ book catalogue

**"Dr Buxton's book is
a must . . . it is
cracking good value"**

GP

Non-specialists overwhelmed by too many systematic descriptions of individual disease will welcome the new approach of the *ABC of Dermatology*. Here the history, clinical appearance, and pathology of a few common key conditions are discussed and then used as a basis for comparison with other skin diseases. Also dealing in detail with allergic reactions, autoimmunity, acne, and infections, this handbook is **fully illustrated in colour**, providing a clear guide to assessment and treatment as well as an understanding of the histological changes underlying the clinical presentations.

"... this little gem is a worthy challenger to all the introductory texts ..."

Journal of the American Academy of Dermatology

"... extremely good value for money."

Contact Dermatitis

"... no hesitation in recommending this book ..."

Occupational Medicine


UK £11.95; Abroad £13.50

BMA members £10.95 or £12.50
including postage, by air abroad

ABC OF DERMATOLOGY

P K BUXTON

BMJ



Available from: **BRITISH MEDICAL JOURNAL**,
PO Box 295, London WC1H 9TE, *medical booksellers*
or the *BMJ bookshop in BMA House*

Please send me _____ copy/ies of
ABC OF DERMATOLOGY

I enclose _____ Please make cheques payable
to **British Medical Journal**

Debit my credit card (please tick box)

☐ Visa ☐ American Express ☐ Mastercard

Card No _____

Card expiry date _____

Signature _____

BMA Membership No _____

NAME _____

ADDRESS _____

POSTCODE _____

☐ Please send me a book catalogue

Are the ills of middle and later life rooted in our early development?



During the past few years a series of articles, mostly from the Medical Research Council's Environmental Epidemiology Unit at the University of Southampton, has been published in leading medical journals. They set out the evidence that certain adult diseases, including coronary heart disease, stroke and diabetes originate in impaired development during fetal life and infancy. Because of the obvious implications for prevention of some of the commonest diseases in Western society, they have attracted international attention. In this book, Professor David Barker, Director of the Unit, has selected 31 articles that he considers seminal and a comprehensive guide to the development of this important topic. Professor Roger Robinson's introduction summarises and interprets the evidence for non-epidemiologists.

The first chapters describe the origins of the hypothesis in geographical studies in England and Wales. These are followed by a series of studies of men and women in middle and late life whose early growth was recorded at the time. In those who have died, cause of death can be related to early growth. Examination of the living has allowed blood pressure, blood lipid and insulin concentrations, and other measurements to be related to different patterns of early growth. Together, the findings show that early development affects the risk of coronary heart disease, stroke, obstructive lung disease and diabetes at least as strongly as obesity, smoking and other aspects of adult life style.

***Fetal and Infant Origins of Adult Disease* brings together in one volume a body of work that cannot be ignored**

Hardback • Illustrations • Tables • 368 pages • ISBN 0-7279-0743-3

UK £24.95; Abroad £30.00 (BMA members £22.95 or £28.00) including postage, by air abroad

ORDER FORM

British Medical Journal, PO Box 295, London WC1H 9TE.

Please send me _____ copy/ies of FETAL AND INFANT ORIGINS OF ADULT DISEASE

NAME _____
(print clearly)

Membership No. _____

ADDRESS _____

Cheque enclosed (made payable to British Medical Journal) £ _____
Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No. _____

Exp. _____

POSTCODE _____

Signature _____

☐ Please send me a book catalogue

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House. Book tokens accepted (UK only).

EUROPE MEETS THE VANCOUVER GROUP

14 January 1993

An invitation to all European medical editors to come and meet members of the International Committee of Medical Journal Editors (the Vancouver Group) and discuss with them key editorial issues.

To coincide with the 1993 meeting of the Vancouver Group (the International Committee of Medical Journal Editors) the *BMJ* and *The Lancet* are hosting a meeting at the Royal Institution of European medical journal editors and members of the Vancouver Group (including the editors of the *Annals of Internal Medicine*, the *Journal of the American Medical Association*, and the *New England Journal of Medicine*). The aim is to allow editors to meet and learn from each other and to influence the issues that the Vancouver Group considers.

The meeting will be followed by an evening reception at BMA House, Tavistock Square, London WC1H 9JA.

All editors of medical journals are welcome to attend.

The Royal Institution,
21 Albemarle Street, London W1
followed by a reception at
BMA House, Tavistock Square,
London WC1H 9JA

Programme

- 10.00** Welcome — Richard Smith, editor, *BMJ*
Robin Fox, editor, *The Lancet*
- 10.05** Developing a journal — Speaker to be announced
- 10.25** Discussion
- 10.35** The search for better referees — Bob and Suzanne Fletcher, editors *Annals of Internal Medicine*
- 11.30** Coffee
- 12.00** What should be on the Vancouver Group agenda? — Magne Nylenna, editor *Norwegian Medical Journal*
George Lundberg, editor *JAMA*
- Group discussions
- 1.15** Lunch
- 2.30** The end of the paper journal? — Speaker to be announced
- 3.15** Should European medical editors join together? — Speakers to be announced
- Group discussions
- 4.40** Summing up — Richard Hughes, editor, *Journal of Neurology, Neurosurgery, and Psychiatry*
- 6.00 - 8.00** Reception, BMA House, Tavistock Square, London WC1H 9JA

Cost (includes lunch): £80
by cheque (enclosing cheque made payable to BMA) to:
Gaby Shockley
BMJ, BMA House,
Tavistock Square,
London WC1H 9JA.

TRADEMARK

Prepulsid

Gets stomach and oesophagus back to work.

Prepulsid. The force behind G.I. motility.

Prescribing information - Prepulsid (cisapride) is a gastro-intestinal prokinetic agent. Prepulsid enhances and co-ordinates gastro-intestinal propulsive motility, thereby preventing stasis and reflux. **Therapeutic indications:** 1. Gastroparesis. 2. Symptoms of X-ray or endoscopy negative upper digestive discomfort. 3. Gastro-oesophageal reflux disorders, including oesophagitis. 4. Intestinal pseudo-obstruction. **Contra-indications:** No absolute contra-indications are known. **Warnings:** Caution should be observed in patients in whom an increase in gastro-intestinal motility could be harmful. **Precautions:** *Pregnancy:* Although, in animals, there is no effect on primary fertility, no primary embryotoxic and no teratogenic effect, the anticipated therapeutic benefits should be weighed against the potential hazards before Prepulsid is given during pregnancy, especially during the first trimester. *Nursing mothers:* Although the excretion in breast milk is minimal, nursing mothers are advised not to breast feed while taking Prepulsid. *Driving and machine-operating ability:* Prepulsid does not affect psychomotor function and does not induce sedation or drowsiness. Prepulsid may, however, accelerate the absorption of central nervous system depressants, such as barbiturates and alcohol. Caution should therefore be exercised when Prepulsid is administered with these drugs. **Interactions:** - The acceleration by Prepulsid of gastric emptying may affect the rate of absorption of drugs: absorption of drugs

from the stomach may be diminished, whereas absorption of drugs from the small bowel may be accelerated (e.g. benzodiazepines, anticoagulants, paracetamol, H₂-blockers). - In patients receiving anticoagulants, the coagulation times may somewhat increase. It is advisable to check the coagulation time one week after the start of Prepulsid treatment to adapt the anticoagulant dose if necessary. The sedative effects of benzodiazepines and of alcohol may be accelerated. - The effects of Prepulsid on gastro-intestinal motility are, for the most part, antagonized by anticholinergic drugs. - In hepatic and renal insufficiency, it is recommended to halve the initial daily dose. Subsequently, this dose can be adapted, depending on the therapeutic effects or possible side-effects. - In the elderly, steady-state plasma levels are generally higher, due to a moderate prolongation of the elimination half-life. Therapeutic doses, however, are similar to those used in younger patients. - In the case of drugs that require individual titration, it may be useful to monitor plasma levels of such drugs when Prepulsid is associated. **Adverse reactions:** In line with the pharmacological activity of Prepulsid, transient abdominal cramping, borborygmi and diarrhoea may occur. Mild and transient headache or lightheadedness have been reported occasionally. When diarrhoea occurs in babies or infants, the dose should be reduced. There are isolated reports of CNS effects, i.e. convulsive seizures and

extrapyramidal effects. **Dosage:** - Adults: according to the severity of the condition, 15 to 40 mg daily, to be given in 2 to 4 intakes, to be taken as tablets or as oral suspension (the full plastic 5-ml spoon contains 5 mg). As a rule the following doses have proven adequate: • less severe conditions: 5 mg t.i.d. (dose can be doubled); • severe conditions (gastroparesis, oesophagitis, refractory constipation): 10 mg t.i.d. to 10 mg q.i.d. (before the 3 main meals and before retiring). - Infants and children: on the average 0.2 mg/kg per intake, 3 to 4 times daily. For the suspension, intakes are indicated on the dosing pipet as a function of body weight.

Full prescribing information available on request.

Note: Prepulsid (cisapride) is not yet available in all countries and not all indications have been approved everywhere.

 **JANSSEN**
PHARMACEUTICA
B-2340 Beerse, Belgium